StreetAlpha.app
Home › Stocks › ACOG

Alpha Cognition Inc. (ACOG)

$7.92
▲ +1.15%
LAST CLOSE · NOV 17

Alpha Cognition develops and sells ZUNVEYL, an oral tablet for Alzheimer's disease. It last closed at $7.92 on Nov 17, up 1.15% on the day. ACOG last reported earnings on Wed, Nov 11, 2026.

AI Auto Pilots
Is ACOG in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$20.2M
Net income
−$28.1M
−139.2% margin
EPS (diluted)
−$1.30
Free cash flow
−$30.8M
−152.7% margin
Valuation
Market cap
$174.6M
22.0M shares
P/E
–
No P/E while losing money
Price to sales
8.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$37.8M
At Sep 30
Shareholder equity
$49.3M
Shares outstanding
22.0M
At Nov 11
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: −$13.8M−$13.8MFY2023FY2024: −$14.8M−$14.8MFY2024FY2025: −$20.7M−$20.7MFY2025

From ACOG's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 11
2026 · After the close (AMC)
Reported EPS
-$0.28
vs -$0.33 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
±15.4%
Priced in before that report
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated ACOG in the past 90 days, not enough for a consensus
Average 12-month target
$21.00
▲ 165.2% upside

Based on 1 analyst who set a price target on ACOG in the past 90 days. The average target is $21.00, with a high of $21.00 and a low of $21.00, compared with the last close of $7.92.

Low $21.00Avg $21.00High $21.00
Blue marker: last close $7.92
Highest target$21.00
Average target$21.00
Lowest target$21.00
Latest rating changes
B. Riley SecuritiesInitiated
Aug 20Buy$21
HC Wainwright & Co.Maintained
Aug 17Buy$20
Raymond JamesInitiated
Jul 10Buy$20
Maxim GroupInitiated
May 29Buy$12
Craig-HallumInitiated
Apr 17Buy$14
DateFirmActionRatingPrice target
Aug 20B. Riley SecuritiesInitiatedBuy$21
Aug 17HC Wainwright & Co.MaintainedBuy$20
Jul 10Raymond JamesInitiatedBuy$20
May 29Maxim GroupInitiatedBuy$12
Apr 17Craig-HallumInitiatedBuy$14
Loading…

Technical Analysis

ACOG · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock is 7% below its 20 day and 9% below its 50 day average. It is 8% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 40). The nearest support is the Pivot S1 at $7.81, and the nearest resistance the Pivot R1 at $8.03.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 6.0%/day
Key levels
$10.1452 week high+28.0%
$8.6750 day average+9.5%
$8.67100 day average+9.5%
$8.65Swing high (Jul 22)+9.2%
$8.5020 day average+7.3%
$8.03Pivot R1+1.4%
$7.92Pivot+0.0%
$7.92Last close
$7.81Pivot S1−1.4%
$7.54Swing low (Jul 31)−4.8%
$7.32200 day average−7.6%
$4.5052 week low−43.2%
Indicators
RSI (14)40.15Middle of its rangeNeutral
MACD-0.15Below its signal lineBearish
Stochastic9.8Near the bottom of its rangeOversold
ADX (14)14.5No clear trend
Williams %R-92.9Oversold below −80, overbought above −20Oversold
CCI (20)-146.5Oversold below −100, overbought above 100Oversold
Rate of change−3.4%Change over 10 sessionsBearish
ATR (14)$0.48Typical daily range, 6.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for ACOG

What happened before

See how ACOG did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in ACOG in the last 90 days.

Loading…

See today’s whale options flow across the market →

ACOG Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲24 buying vs 10 selling
  • ▲Held by funds +0.6 pts
  • ▲Funds holding +16
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding4226+61.5%
In funds' top 1031+200.0%
Held by funds48.7%48.1%+0.6 pts
New / increased18 / 61 / 7+200.0%
Reduced / sold out8 / 24 / 0+150.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ACOG institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACOG is in one of them and how their past ACOG trades turned out.

ACOG in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ACOG in an article yet. Here's the latest on the wider market.

About Alpha Cognition

Alpha Cognition is a biopharmaceutical company based in Grapevine, Texas, that develops treatments for neurodegenerative diseases, with a focus on Alzheimer's disease. Its main product is ZUNVEYL, an oral tablet for mild to moderate dementia of the Alzheimer's type. The company sells ZUNVEYL to nursing homes that care for Alzheimer's patients, working with physicians, pharmacies and pharmacy benefit managers to expand access. It also has earlier stage programs and has licensed ZUNVEYL rights in parts of Asia, Australia and New Zealand.

Headquarters
Grapevine, TX